Cargando…
Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy
Tumor nanovaccines have potential applications in the prevention and treatment of malignant tumors. However, it remains a longstanding challenge in exploiting efficient nanocarriers for inducing potent specifically cellular immune responses. Toward this objective, we herein explore an intensive tumo...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379363/ https://www.ncbi.nlm.nih.gov/pubmed/34466725 http://dx.doi.org/10.1016/j.bioactmat.2021.05.036 |
_version_ | 1783740989774495744 |
---|---|
author | Chen, Jie Fang, Huapan Hu, Yingying Wu, Jiayan Zhang, Sijia Feng, Yuanji Lin, Lin Tian, Huayu Chen, Xuesi |
author_facet | Chen, Jie Fang, Huapan Hu, Yingying Wu, Jiayan Zhang, Sijia Feng, Yuanji Lin, Lin Tian, Huayu Chen, Xuesi |
author_sort | Chen, Jie |
collection | PubMed |
description | Tumor nanovaccines have potential applications in the prevention and treatment of malignant tumors. However, it remains a longstanding challenge in exploiting efficient nanocarriers for inducing potent specifically cellular immune responses. Toward this objective, we herein explore an intensive tumor immunotherapeutic strategy by combining mannosylated nanovaccines and gene regulated PD-L1 blockade for immune stimulation and killing activity. Here, we fabricate a mannose modified PLL-RT (Man-PLL-RT) mediated nanovaccines with dendritic cells (DCs) targeting capacity. Man-PLL-RT is capable of co-encapsulating with antigen (ovalbumin, OVA) and adjuvant (unmethylated cytosine-phosphate-guanine, CpG) by electrostatic interaction. This positively charged Man-PLL-RT/OVA/CpG nanovaccines can facilitate the endocytosis, maturation and cross presentation in DCs. However, the nanovaccines arouse limited inhibition of tumor growth, which is mainly due to the immunosuppressed microenvironment of tumors. Combining tumor nanovaccines with gene regulated PD-L1 blockade leads to an obvious tumor remission in B16F10 melanoma bearing mice. The collaborative strategy provides essential insights to boost the benefits of tumor vaccines by regulating the checkpoint blockade with gene therapy. |
format | Online Article Text |
id | pubmed-8379363 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | KeAi Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-83793632021-08-30 Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy Chen, Jie Fang, Huapan Hu, Yingying Wu, Jiayan Zhang, Sijia Feng, Yuanji Lin, Lin Tian, Huayu Chen, Xuesi Bioact Mater Article Tumor nanovaccines have potential applications in the prevention and treatment of malignant tumors. However, it remains a longstanding challenge in exploiting efficient nanocarriers for inducing potent specifically cellular immune responses. Toward this objective, we herein explore an intensive tumor immunotherapeutic strategy by combining mannosylated nanovaccines and gene regulated PD-L1 blockade for immune stimulation and killing activity. Here, we fabricate a mannose modified PLL-RT (Man-PLL-RT) mediated nanovaccines with dendritic cells (DCs) targeting capacity. Man-PLL-RT is capable of co-encapsulating with antigen (ovalbumin, OVA) and adjuvant (unmethylated cytosine-phosphate-guanine, CpG) by electrostatic interaction. This positively charged Man-PLL-RT/OVA/CpG nanovaccines can facilitate the endocytosis, maturation and cross presentation in DCs. However, the nanovaccines arouse limited inhibition of tumor growth, which is mainly due to the immunosuppressed microenvironment of tumors. Combining tumor nanovaccines with gene regulated PD-L1 blockade leads to an obvious tumor remission in B16F10 melanoma bearing mice. The collaborative strategy provides essential insights to boost the benefits of tumor vaccines by regulating the checkpoint blockade with gene therapy. KeAi Publishing 2021-06-04 /pmc/articles/PMC8379363/ /pubmed/34466725 http://dx.doi.org/10.1016/j.bioactmat.2021.05.036 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Chen, Jie Fang, Huapan Hu, Yingying Wu, Jiayan Zhang, Sijia Feng, Yuanji Lin, Lin Tian, Huayu Chen, Xuesi Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy |
title | Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy |
title_full | Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy |
title_fullStr | Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy |
title_full_unstemmed | Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy |
title_short | Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy |
title_sort | combining mannose receptor mediated nanovaccines and gene regulated pd-l1 blockade for boosting cancer immunotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379363/ https://www.ncbi.nlm.nih.gov/pubmed/34466725 http://dx.doi.org/10.1016/j.bioactmat.2021.05.036 |
work_keys_str_mv | AT chenjie combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy AT fanghuapan combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy AT huyingying combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy AT wujiayan combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy AT zhangsijia combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy AT fengyuanji combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy AT linlin combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy AT tianhuayu combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy AT chenxuesi combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy |